...
首页> 外文期刊>Current Surgery Reports >Minimization of Immunosuppression and Tolerance Induction in Reconstructive Transplantation
【24h】

Minimization of Immunosuppression and Tolerance Induction in Reconstructive Transplantation

机译:重建移植中的免疫抑制和耐受诱导最小化

获取原文
获取原文并翻译 | 示例

摘要

Vascularized composite allotransplantation (VCA) is an innovative reconstructive modality for patients sustaining complex injuries not amenable to conventional treatment. Advances in immunosuppression have made VCA a clinical reality and a valid reconstructive option for such patients. The requirement, however, for multi-drug high-dose immunosuppressive regimens with their numerous side effects has hindered widespread clinical application of VCA. There is thus a need for novel immunologic modalities to minimize or even obviate the need for immunosuppression (tolerance induction) while still preserving the allograft and preventing rejection. Recent advances in targeted immunotherapy and cell-based protocols were able to achieve tolerance in selected cases of solid organ transplantation. This paved the way for innovative immunomodulatory protocols now also applied to VCA that aim for minimal immunosuppression or for induction of donor-specific tolerance. These concepts and novel protocols will be discussed in this review.
机译:血管化复合同种异体移植(VCA)是一种创新的重建方式,适用于遭受传统疗法无法承受的复杂损伤的患者。免疫抑制的进展已使VCA成为临床现实,并成为此类患者的有效重建选择。然而,对具有多种副作用的多药高剂量免疫抑制方案的要求阻碍了VCA的广泛临床应用。因此,需要新的免疫学方法以最小化或什至消除对免疫抑制(耐受性诱导)的需要,同时仍保留同种异体移植物并防止排斥。靶向免疫疗法和基于细胞的治疗方案的最新进展能够在选定的实体器官移植病例中实现耐受性。这为现在也应用于VCA的创新免疫调节方案铺平了道路,该方案旨在最小化免疫抑制或诱导供体特异性耐受。这些概念和新颖的协议将在本文中进行讨论。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号